Current Report


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K

 

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (date of earliest event reported): May 14, 2015


Heat Biologics, Inc.

(Exact name of registrant as specified in charter)


Delaware

(State or other jurisdiction of incorporation)

 

001-35994

26-2844103

(Commission File Number)

(IRS Employer Identification No.)


801 Capitola Drive

Durham, NC  27713

(Address of principal executive offices and zip code)


(919) 240-7133

(Registrant’s telephone number including area code)

 

N/A

(Former Name and Former Address)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


 

¨

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)


 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

 




 


Item 2.02 – Results of Operations and Financial Condition.


On May 14, 2015, Heat Biologics, Inc., a Delaware corporation (the “Registrant") issued a press release that included financial information for the quarter ended March 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

 

Item 9.01 – Financial Statements and Exhibits.

 

(d)  

Exhibits.

 

 

 

The following exhibit is being filed as part of this Report.

 

Exhibit
Number

 

 Description

 

 

 

99.1

 

Press Release issued by Heat Biologics, Inc., dated May 14, 2015

 

 

 


 












  

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated:  May 14, 2015

HEAT BIOLOGICS, INC.

 

 

 

 

 

 

By:

/s/ Jeff Wolf

 

Name:

Jeff Wolf

 

Title:

Chairman, President and

Chief Executive Officer











EXHIBIT INDEX



Exhibit

Number

 

Description

 

 

99.1

Press Release issued by Heat Biologics, Inc., dated May 14, 2015